Keeping Track: Alkermes' Aristada Approval; Bristol's Daklinza Submission; Lilly's Breakthrough

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from Approvals

More from Product Reviews